ストックスクリーナーアプリを入手
0.1703
5.25%
0.0085
アフターアワーズ：
.17
-0.0003
-0.18%
前日終値:
$0.1618
開ける：
$0.1599
24時間の取引高:
1.02M
Relative Volume:
1.41
時価総額：
$6.79M
収益：
$94,000
当期純損益:
$-13.28M
株価収益率:
-0.0233
EPS:
-7.2965
ネットキャッシュフロー:
$-11.67M
1週間 パフォーマンス:
-5.18%
1か月 パフォーマンス:
-20.27%
6か月 パフォーマンス:
-68.79%
1年 パフォーマンス:
-93.57%
1日の値動き範囲:
$0.1599
$0.1756
1週間の範囲:
$0.1599
$0.183
52週間の値動き範囲:
$0.1599
$2.8771
AIM ImmunoTech Inc Stock (AIM) Company Profile
Compare AIM vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
0.1703 | 6.79M | 94,000 | -13.28M | -11.67M | -7.2965 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
AIM ImmunoTech Inc (AIM) 最新ニュース
AIM ImmunoTech Highlights Recent Media Coverage of - GlobeNewswire
AIM ImmunoTech Highlights Recent Media Coverage of - GlobeNewswire
AIM ImmunoTech Spotlights Growing Attention Around - GlobeNewswire
57 patients with stable pancreatic cancer received an immune-modulating drug after chemotherapy. - Stock Titan
AIM ImmunoTech Spotlights Growing Attention Around - GlobeNewswire
AIM ImmunoTech Discusses Ampligen®’s Potential to - GlobeNewswire
AIM ImmunoTech Announces Virtual 2026 Annual Stockholders Meeting and Proxy Details - Kalkine Media
AIM ImmunoTech Submits 2025 Annual Report Highlighting Focus on Ampligen for Pancreatic Cancer - Kalkine Media
AIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video - The Manila Times
A 39-patient exploratory analysis reported 34.8 months’ median survival in pancreatic cancer. - Stock Titan
AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib - markets.businessinsider.com
AIM Looks 71.3% Undervalued on GF Value™ Despite Financial Strug - GuruFocus
AIM ImmunoTech Highlights Ampligen’s Potential Role in the - globenewswire.com
AIM ImmunoTech Inc Share PriceAIM, RNS News, Articles, Quotes, & Charts (AMEX:AIM) - Proactive financial news
Aim Immunotech Stock Price Forecast. Should You Buy AIM? - StockInvest.us
Aim ImmunoTech CEO Equels buys $4,992 in stock - Investing.com
Aim ImmunoTech CEO & president buys $2,310 in company stock - Investing.com
Aim ImmunoTech CEO & President Thomas Equels buys $4,862 in stock - Investing.com
AIM ImmunoTech Reduces Debt via Equity Exchange Agreements - The Globe and Mail
AIM ImmunoTech Reduces Debt via Equity Exchange Agreements - TipRanks
AIM ImmunoTech Converts ~$450,000 of Note Into 1.92M Shares in Exchanges With Streeterville - TradingView
AIM ImmunoTech Highlights Scientific Rationale, Supportive - GlobeNewswire
AIM ImmunoTech Highlights Scientific Rationale, Supportive - GlobeNewswire
AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video - Yahoo Finance
AIM ImmunoTech Eliminates $1.22 Million Debt via Stock Exchange - minichart.com.sg
AIM ImmunoTech Extinguishes Debt Through Equity Exchanges - TipRanks
AIM ImmunoTech Secures Ampligen Patent Protection in Europe - Intellectia AI
AIM ImmunoTech Significantly Expands Ampligen® Global - GlobeNewswire
AIM ImmunoTech Significantly Expands Ampligen® Global - GlobeNewswire
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041 - The Manila Times
AIM ImmunoTech Secures European and U.K. Patent Protection for Ampligen in Long COVID Through 2041 - Quiver Quantitative
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041 - Yahoo Finance
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041 - GlobeNewswire
AIM ImmunoTech Extends IP Protection for Ampligen Through 2039 with Broad US Patent - Contract Pharma
AIM Looks 69.6% Undervalued on GF Value™ Despite Financial Distr - GuruFocus
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039 - The Manila Times
AIM ImmunoTech Secures U.S. Patent for Ampligen Combination with Pembrolizumab in Cancer Treatment - Quiver Quantitative
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod - GlobeNewswire
AIM patent covers Ampligen with Keytruda across cancers through 2039 - Stock Titan
AIM Q2 2026 Earnings: Wider Than-Expected Loss as Clinical-Stage Costs PersistProfit Inflection Point - vinanet.vn
AIM ImmunoTech Inc. (AIM) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
AIM ImmunoTech Inc. (AIM) Key Financial Ratios – Valuation, Profitability & More - Value Research
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference - manilatimes.net
AIM ImmunoTech doses final patient in pancreatic cancer trial - stocktitan.net
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference - Yahoo Finance
AIM ImmunoTech Participates in the Virtual Investor 'Why Now' On-Demand Conference - Moomoo
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference - GlobeNewswire
AIM | AIM ImmunoTech Inc. FinancialsRevenue Breakdown - quiverquant.com
AIM ImmunoTech (AIM) Stock Forecast & Analyst Ratings - Moomoo
AIM Maintained by Ascendiant Capital -- Price Target Lowered to $7.00 - GuruFocus
AIM ImmunoTech Inc (AIM) 財務データ
収益
当期純利益
現金流量
EPS
AIM ImmunoTech Inc (AIM) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Equels Thomas K | CEO & President |
Sep 16 '26 |
Buy |
0.21 |
11,000 |
2,310 |
102,822 |
| Equels Thomas K | CEO & President |
Sep 15 '26 |
Buy |
0.22 |
22,000 |
4,862 |
91,822 |
| Equels Thomas K | CEO & President |
Sep 14 '26 |
Buy |
0.22 |
5,900 |
1,292 |
69,822 |
1.35%
大文字化:
|
ボリューム (24 時間):